SLC2A1 and Dravet syndrome: In the case of GLUT1-DS, Angeli et al. (2023a) developed a series of compounds with dual targeting capabilities, designed to target either hCA isoforms or GLUT1 transporters as key targets of GLUT1-DS associated seizures (Klepper et al., 2020).